Vaccinia virus: a tool for research and vaccine development.

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature (2011) 4.61

Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A (1992) 4.58

Assembly of vaccinia virus: role of the intermediate compartment between the endoplasmic reticulum and the Golgi stacks. J Cell Biol (1993) 4.34

Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A (1996) 3.29

Identification of human cancers deficient in antigen processing. J Exp Med (1993) 3.21

Stringent chemical and thermal regulation of recombinant gene expression by vaccinia virus vectors in mammalian cells. Proc Natl Acad Sci U S A (1995) 2.45

Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol (1995) 2.45

Reduced O glycosylation of Sp1 is associated with increased proteasome susceptibility. Mol Cell Biol (1997) 2.45

Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci U S A (1993) 2.44

Assembly of vaccinia virus: effects of rifampin on the intracellular distribution of viral protein p65. J Virol (1994) 2.17

Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci U S A (1997) 2.11

PGP4, an ATP binding cassette P-glycoprotein, catalyzes auxin transport in Arabidopsis thaliana roots. Plant Cell (2005) 2.08

The envelope protein encoded by the A33R gene is required for formation of actin-containing microvilli and efficient cell-to-cell spread of vaccinia virus. J Virol (1998) 2.05

Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene. J Virol (1996) 2.03

IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol (1995) 2.02

Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacterium Streptococcus gordonii after oral colonization. Proc Natl Acad Sci U S A (1995) 1.80

Inactivated influenza virus, when presented on dendritic cells, elicits human CD8+ cytolytic T cell responses. J Exp Med (1995) 1.78

Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1. J Virol (1993) 1.70

Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc Natl Acad Sci U S A (1999) 1.63

Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques. J Virol (1999) 1.60

Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest (2004) 1.58

Modulating the function of the measles virus RNA-dependent RNA polymerase by insertion of green fluorescent protein into the open reading frame. J Virol (2002) 1.51

IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J Immunol (1996) 1.49

Protection against apoptosis by the vaccinia virus SPI-2 (B13R) gene product. J Virol (1996) 1.48

O glycosylation of an Sp1-derived peptide blocks known Sp1 protein interactions. Mol Cell Biol (1997) 1.47

Assembly of vaccinia virus: incorporation of p14 and p32 into the membrane of the intracellular mature virus. J Virol (1995) 1.47

Identification of an immunoreactive Brucella abortus HtrA stress response protein homolog. Infect Immun (1994) 1.47

Identification of multiple SRF N-terminal phosphorylation sites affecting DNA binding properties. EMBO J (1992) 1.44

Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol (1996) 1.44

Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein. J Virol (1998) 1.42

Protection against lethal lymphocytic choriomeningitis virus (LCMV) infection by immunization of mice with an influenza virus containing an LCMV epitope recognized by cytotoxic T lymphocytes. J Virol (1994) 1.40

Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA. J Immunol (1993) 1.39

The pathway and targeting signal for delivery of the integral membrane glycoprotein LEP100 to lysosomes. J Cell Biol (1992) 1.36

Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J Virol (1996) 1.33

Classical swine fever virus: independent induction of protective immunity by two structural glycoproteins. J Virol (1995) 1.28

Use of licensed vaccines for active immunization of the immunocompromised host. Clin Microbiol Rev (1998) 1.26

Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest (2005) 1.24

Vaccinia virus-specific CD8+ cytotoxic T lymphocytes in humans. J Virol (1993) 1.23

Identification, analysis, and evolutionary relationships of the putative murine cytomegalovirus homologs of the human cytomegalovirus UL82 (pp71) and UL83 (pp65) matrix phosphoproteins. J Virol (1996) 1.18

trans activation by the full-length E2 proteins of human papillomavirus type 16 and bovine papillomavirus type 1 in vitro and in vivo: cooperation with activation domains of cellular transcription factors. J Virol (1994) 1.13

Structure of intracellular mature vaccinia virus visualized by in situ atomic force microscopy. J Virol (2003) 1.13

Functional characterization of a glycine 185-to-valine substitution in human P-glycoprotein by using a vaccinia-based transient expression system. Mol Biol Cell (1996) 1.11

Stable expression of the vaccinia virus K1L gene in rabbit cells complements the host range defect of a vaccinia virus mutant. J Virol (1994) 1.09

Envelope formation is blocked by mutation of a sequence related to the HKD phospholipid metabolism motif in the vaccinia virus F13L protein. J Virol (1999) 1.08

A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia. Blood (2008) 1.07

Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL. J Immunol (1995) 1.07

Human immunodeficiency virus vaccine trials. Cold Spring Harb Perspect Med (2012) 1.05

Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccin Immunother (2012) 1.00

Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination. Vaccine (2007) 0.98

Expression of Aleutian mink disease parvovirus capsid proteins by a recombinant vaccinia virus: self-assembly of capsid proteins into particles. J Virol (1992) 0.97

A change in gating mode leading to increased intrinsic Cl- channel activity compensates for defective processing in a cystic fibrosis mutant corresponding to a mild form of the disease. EMBO J (1995) 0.95

An HLA-DRw53-restricted T-cell epitope from a novel Mycobacterium leprae protein antigen important to the human memory T-cell repertoire against M. leprae. Infect Immun (1994) 0.95

Nuclear localization of the PEP protein tyrosine phosphatase. Mol Cell Biol (1994) 0.94

Evaluation of Toxoplasma gondii as a live vaccine vector in susceptible and resistant hosts. Parasit Vectors (2011) 0.92

Expression of hepatitis E virus putative structural proteins in recombinant vaccinia viruses. Clin Diagn Lab Immunol (1994) 0.92

The 35-kilodalton protein gene (p35) of Autographa californica nuclear polyhedrosis virus and the neomycin resistance gene provide dominant selection of recombinant baculoviruses. Nucleic Acids Res (1993) 0.91

Induction of antigen-specific class I-restricted cytotoxic T cells by soluble proteins in vivo. Proc Natl Acad Sci U S A (1992) 0.90

Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses. Cancer Res (1995) 0.90

JNK-deficiency enhanced oncolytic vaccinia virus replication and blocked activation of double-stranded RNA-dependent protein kinase. Cancer Gene Ther (2008) 0.90

Pasteurella multocida produces a protein with homology to the P6 outer membrane protein of Haemophilus influenzae. Infect Immun (1995) 0.88

Studies of human MDR1-MDR2 chimeras demonstrate the functional exchangeability of a major transmembrane segment of the multidrug transporter and phosphatidylcholine flippase. Mol Cell Biol (1999) 0.88

Translation of reovirus RNA species m1 can initiate at either of the first two in-frame initiation codons. Proc Natl Acad Sci U S A (1993) 0.87

Theranostic potential of oncolytic vaccinia virus. Theranostics (2012) 0.86

Viral vector vaccines make memory T cells against malaria. Immunology (2007) 0.86

A novel high-throughput vaccinia virus neutralization assay and preexisting immunity in populations from different geographic regions in China. PLoS One (2012) 0.86

The next wave of recombinant and synthetic anticancer vaccines. Semin Cancer Biol (1995) 0.85

Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen. J Natl Cancer Inst (1999) 0.84

Genome-wide profiling of human cap-independent translation-enhancing elements. Nat Methods (2013) 0.84

Autoantigens plus interleukin-10 suppress diabetes autoimmunity. Diabetes Technol Ther (2010) 0.83

Activation of the human immunodeficiency virus type 1 long terminal repeat by vaccinia virus. J Virol (1992) 0.83

Identification and characterization of a 14-kilodalton Brucella abortus protein reactive with antibodies from naturally and experimentally infected hosts and T lymphocytes from experimentally infected BALB/c mice. Infect Immun (1998) 0.83

Multiple viral ligands naturally presented by different class I molecules in transporter antigen processing-deficient vaccinia virus-infected cells. J Virol (2011) 0.83

Cloning and partial characterization of the mouse glutamine:fructose-6-phosphate amidotransferase (GFAT) gene promoter. Nucleic Acids Res (1997) 0.81

Expression of functional recombinant human procathepsin B in mammalian cells. Biochem J (1996) 0.81

Enhancing the recognition of tumour associated antigens. Folia Biol (Praha) (1994) 0.80

Vaccinia virus replication is not affected by APOBEC3 family members. Virol J (2006) 0.80

New classes of orthopoxvirus vaccine candidates by functionally screening a synthetic library for protective antigens. Virology (2009) 0.80

Subcellular forms and biochemical events triggered in human cells by HCV polyprotein expression from a viral vector. Virol J (2008) 0.79

A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responses. PLoS One (2013) 0.78

Fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus induce neutralizing antibodies and reduce viremia in chickens. J Virol (1993) 0.77

Structure and Metal Binding Properties of a Poxvirus Resolvase. J Biol Chem (2016) 0.76

Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications. Vaccines (Basel) (2014) 0.75

Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development. World J Urol (2000) 0.75

A viral, transporter associated with antigen processing (TAP)-independent, high affinity ligand with alternative interactions endogenously presented by the nonclassical human leukocyte antigen E class I molecule. J Biol Chem (2012) 0.75

Poxvirus expression vectors. Curr Top Microbiol Immunol (1992) 0.85

Recombinant DNA virus vectors for vaccination. Semin Immunol (1990) 0.76